drugset / Trial / NCT07319871
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.
Timeline
- Start
- 2026-01-14
- Primary completion
- 2027-01-07
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-86974680 | Unknown | — | Oral |
| Subject | Pasritamig | Other / unclassified | — | Intravenous |